Diagnosis of latent tuberculosis and prevention of reactivation in rheumatic patients receiving biologic therapy: International recommendations

Journal of Rheumatology

Volumn 41, Issue SUPPL. 91, 2014, Pages 41-46

  Iannone, Florenzo ^a   Cantini, Fabrizio ^b   Lapadula, Giovanni ^a  

^a UNIVERSITY OF BARI   (Italy)

^b Ospedale di Prato   (Italy)

Author keywords

Anti Tumor Necrosis Factor a Agents; Mycobacterium Tuberculosis; Tst Igra

Indexed keywords

BCG VACCINE; GLUCOCORTICOID; ISONIAZID; PREDNISOLONE; PYRAZINAMIDE; RIFAMPICIN; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; BIOLOGICAL PRODUCT;

ANTIGEN FUNCTION; ARTICLE; BIOLOGICAL THERAPY; CHEMOPROPHYLAXIS; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; DISEASE PREDISPOSITION; DRUG EFFICACY; FALSE NEGATIVE RESULT; FALSE POSITIVE RESULT; HUMAN; IMMUNOREACTIVITY; INFECTION PREVENTION; INFECTION RISK; INTERFERON GAMMA RELEASE ASSAY; LATENT TUBERCULOSIS; MEDICAL HISTORY; POSTPRIMARY TUBERCULOSIS; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTOCOL COMPLIANCE; RESCREENING; RHEUMATIC DISEASE; RISK ASSESSMENT; SKIN INDURATION; THORAX RADIOGRAPHY; TREATMENT DURATION; TUBERCULIN TEST; TUBERCULOSIS; PRACTICE GUIDELINE; RHEUMATIC DISEASES; SECONDARY PREVENTION;

BIOLOGICAL PRODUCTS; HUMANS; LATENT TUBERCULOSIS; PRACTICE GUIDELINES AS TOPIC; RHEUMATIC DISEASES; SECONDARY PREVENTION;

EID: 84899834072     PISSN: 0315162X     EISSN: 14992752     Source Type: Journal    
DOI: 10.3899/jrheum.140101     Document Type: Article

References (29)

1. Fallahi-Sichani M, El-Kebir M, Marino S, Kirschner DE, Linderman JJ. Multiscale computational modeling reveals a critical role for TNF-a receptor 1 dynamics in tuberculosis granuloma formation. J Immunol 2011;186:3472-83
2. Keane J, Gershon S, Wise RP, Mirabile-Levens E, Kasznica J, Schwieterman WD, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 2001;345:1098-104
3. Askling J, Fored CM, Brandt L, Baecklund E, Bertilsson L, Cöster L, et al. Risk and case characteristics of tuberculosis in rheumatoid arthritis associated with tumor necrosis factor antagonists in Sweden. Arthritis Rheum 2005;52:1986-92 (Pubitemid 40994319)
4. Brassard P, Lowe AM, Bernatsky S, Kezouh A, Suissa S. Rheumatoid arthritis, its treatments, and the risk of tuberculosis in Quebec, Canada. Arthritis Rheum 2009;61:300-4
5. Carmona L, Hernández-García C, Vadillo C, Pato E, Balsa A, González-Alvaro I, et al. Increased risk of tuberculosis in patients with rheumatoid arthritis. J Rheumatol 2003;30:1436-9 (Pubitemid 36835436)
6. Dixon WG, Hyrich KL, Watson KD, Lunt M, Galloway J, Ustianowski A, et al. Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR). Ann Rheum Dis 2010;69:522-8
7. Gómez-Reino JJ, Carmona L, Angel Descalzo M, Biobadaser Group. Risk of tuberculosis in patients treated with tumor necrosis factor antagonists due to incomplete prevention of reactivation of latent infection. Arthritis Rheum 2007;57:756-61 (Pubitemid 46932080)
8. Seong SS, Choi CB, Woo JH, Bae KW, Joung CL, Uhm WS, et al. Incidence of tuberculosis in Korean patients with rheumatoid arthritis (RA): effects of RA itself and of tumor necrosis factor blockers. J Rheumatol 2007;34:706-11
9. Tubach F, Salmon D, Ravaud P, Allanore Y, Goupille P, Bréban M, et al. Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: The three-year prospective French Research Axed on Tolerance of Biotherapies registry. Arthritis Rheum 2009;60:1884-94
10. Harbour R, Miller J. A new system for grading recommendations in evidence based guidelines. BMJ 2001;323:334-6 (Pubitemid 32744465)
11. Mariette X, Salmon D. French guidelines for diagnosis and treating latent and active tuberculosis in patients with RA treated with TNF blockers. Ann Rheum Dis 2003;62:791. (Pubitemid 36886422)
12. Carmona L, Gómez-Reino JJ, Rodríguez-Valverde V, Montero D, Pascual-Gómez E, Mola EM, et al. Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists. Arthritis Rheum 2005;52:1766-72 (Pubitemid 40852885)
13. British Thoracic Society Standards of Care Committee. BTS recommendations for assessing risk and for managing Mycobacterium tuberculosis infection and disease in patients due to start anti-TNF-alpha treatment. Thorax 2005;60:800-5
14. Koike R, Takeuchi T, Eguchi K, Miyasaka N, Japan College of Rheumatology. Update on the Japanese guidelines for the use of infliximab and etanercept in rheumatoid arthritis. Mod Rheumatol 2007;17:451-8
15. Beglinger C, Dudler J, Mottet C, Nicod L, Seibold F, Villiger PM, et al. Screening for tuberculosis infection before initiation of anti-TNF-alpha therapy. Swiss Med Wkly 2007;137:621
16. Australian Rheumatology Association. Updated recommendations for the use of biological agents for the treatment of rheumatic diseases. Revised 2011. [Internet. Accessed February 24, 2014.] Available from: http://www.rheumatology. org.au/downloads/FINAL-BiologicalRecommendations060111.pdf
17. Favalli EG, Caporali R, Sinigaglia L, Pipitone N, Miniati I, Montecucco C, et al. Recommendations for the use of biologic therapy in rheumatoid arthritis: update from the Italian Society for Rheumatology II. Safety. Clin Exp Rheumatol 2011;29:S15-27
18. Singh JA, Furst DE, Bharat A, Curtis JR, Kavanaugh AF, Kremer JM, et al. 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res 2012;64:625-39
19. Bombardier C, Hazlewood GS, Akhavan P, Schieir O, Dooley A, Haraoui B, et al. Canadian Rheumatology Association recommendations for the pharmacological management of rheumatoid arthritis with traditional and biologic disease-modifying antirheumatic drugs: part II safety. J Rheumatol 2012;39:1583-602
20. Bélard E, Semb S, Ruhwald M, Werlinrud AM, Soborg B, Jensen FK, et al. Prednisolone treatment affects the performance of the QuantiFERON gold in-tube test and the tuberculin skin test in patients with autoimmune disorders screened for latent tuberculosis infection. Inflamm Bowel Dis 2011;17:2340-9
21. Furst DE, Cush J, Kaufmann S, Siegel J, Kurth R. Preliminary guidelines for diagnosing and treating tuberculosis in patients with rheumatoid arthritis in immunosuppressive trials or being treated with biological agents. Ann Rheum Dis 2002;61 Suppl 2:ii62-3
22. Solovic I, Sester M, Gomez-Reino JJ, Rieder HL, Ehlers S, Milburn HJ, et al. The risk of tuberculosis related to tumour necrosis factor antagonist therapies: a TBNET consensus statement. Eur Respir J 2010;36:1185-206
23. Kim EM, Uhm WS, Bae SC, Yoo DH, Kim TH. Incidence of tuberculosis among Korean patients with ankylosing spondylitis who are taking tumor necrosis factor blockers. J Rheumatol 2011;38:2218-23
24. Sichletidis L, Settas L, Spyratos D, Chloros D, Patakas D. Tuberculosis in patients receiving anti-TNF agents despite chemoprophylaxis. Int J Tuberc Lung Dis 2006;10:1127-32 (Pubitemid 44519351)
25. Aggarwal R, Manadan AM, Poliyedath A, Sequeira W, Block JA. Safety of etanercept in patients at high risk for mycobacterial tuberculosis infections. J Rheumatol 2009;36:914-7
26. Diel R, Loddenkemper R, Meywald-Walter K, Niemann S, Nienhaus A. Predictive value of a whole blood IFN-gamma assay for the development of active tuberculosis disease after recent infection with Mycobacterium tuberculosis. Am J Respir Crit Care Med 2008;177:1164-70 (Pubitemid 351717577)
27. Park JH, Seo GY, Lee JS, Kim TH, Yoo DH. Positive conversion of tuberculin skin test and performance of interferon release assay to detect hidden tuberculosis infection during anti-tumor necrosis factor agent trial. J Rheumatol 2009;36:2158-63
28. John H, Buckley C, Koh L, Obrenovic K, Erb N, Rowe IF, West Midlands Rheumatology Service and Training Committee. Regional survey of tuberculosis risk assessment in rheumatology outpatients commencing anti-TNF-alpha treatment in relation to British Thoracic Society guidelines. Clin Med 2009;9:225-30
29. Hsia EC, Cush JJ, Matteson EL, Beutler A, Doyle MK, Hsu B, et al. Comprehensive tuberculosis screening program in patients with inflammatory arthritides treated with golimumab, a human anti-tumor necrosis factor antibody, in Phase III clinical trials. Arthritis Care Res 2013;65:309-13